TScan Therapeutics, Inc.
TCRX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001783328
No open-market purchases or sales by TScan Therapeutics, Inc. insiders were filed in the last 90 days; 60 institutions reported holding it in 13F filings for Q2 2026, worth $35.1M in total; no superinvestor holds it.
Q4 2022 vs. Q3 2022
How the institutions holding TScan Therapeutics, Inc. changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Q4 2022 | Change |
|---|---|---|---|
| Holders | 26 | 28 | +2 |
| Shares | 9.51M | 9.52M | +11.0K (+0.1%) |
| Value | $29.0M | $14.8M | −$14.2M (−49.0%) |
New holders (5)
Institutions that held TScan Therapeutics, Inc. at the end of Q4 2022 but not at the end of Q3 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| NewEdge Wealth, LLC | 91,463 | $141.8K | 0.01% |
| Millennium Management LLC | 19,244 | $31.0K | 0.00% |
| Northern Trust Corp | 11,245 | $17.4K | 0.00% |
| Renaissance Technologies LLC | 10,000 | $16.0K | 0.00% |
| Bank of America Corp | 234 | $362 | 0.00% |
Sold out (3)
Institutions that held TScan Therapeutics, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Woodline Partners LP | 66,601 | $203.0K |
| Marquette Asset Management, LLC | 28,895 | $88.0K |
| Royal Bank of Canada | 184 | $1.00K |